These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31291219)

  • 41. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
    Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
    J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
    Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
    J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.
    Azorin JM; Sapin C; Weiller E
    J Affect Disord; 2013 Feb; 145(1):62-9. PubMed ID: 22868059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
    Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
    J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
    Mahajan V; Arora M; Tandon VR; Gillani Z; Praharaj SK
    J Clin Psychopharmacol; 2019; 39(4):305-311. PubMed ID: 31205195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
    Gerrits M; de Greef R; Peeters P
    Biopharm Drug Dispos; 2010 Jul; 31(5-6):351-7. PubMed ID: 20549835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Asenapine: a less effective, yet, more dangerous neuroleptic!
    Prescrire Int; 2012 Oct; 21(131):229-32. PubMed ID: 23185842
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder.
    Ketter TA; Durgam S; Landbloom R; Mackle M; Wu X; Mathews M
    J Affect Disord; 2017 Jan; 207():384-392. PubMed ID: 27755982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.
    Szegedi A; Durgam S; Mackle M; Yu SY; Wu X; Mathews M; Landbloom RP
    Am J Psychiatry; 2018 Jan; 175(1):71-79. PubMed ID: 28946761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice].
    Samalin L; Tixeront C; Llorca PM
    Encephale; 2012 Jun; 38(3):257-65. PubMed ID: 22726414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ▼Asenapine for bipolar I disorder?
    Drug Ther Bull; 2012 Jun; 50(6):69-72. PubMed ID: 22700206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Asenapine in the treatment of older adults with bipolar disorder.
    Sajatovic M; Dines P; Fuentes-Casiano E; Athey M; Cassidy KA; Sams J; Clegg K; Locala J; Stagno S; Tatsuoka C
    Int J Geriatr Psychiatry; 2015 Jul; 30(7):710-9. PubMed ID: 25335125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.
    Caresano C; Di Sciascio G; Fagiolini A; Maina G; Perugi G; Ripellino C; Vampini C
    Adv Ther; 2014 Aug; 31(8):873-90. PubMed ID: 25055791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
    McIntyre RS; Tohen M; Berk M; Zhao J; Weiller E
    J Affect Disord; 2013 Sep; 150(2):378-83. PubMed ID: 23712026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Asenapine versus olanzapine in acute mania: a double-blind extension study.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    Bipolar Disord; 2009 Dec; 11(8):815-26. PubMed ID: 19832806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paradoxical pinpoint pupils with asenapine.
    Gill JS; Jambunathan S; Wong S; Wong A
    Asia Pac Psychiatry; 2015 Jun; 7(2):230. PubMed ID: 25923587
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
    Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
    Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Asenapine in the Treatment of Acute Mania: A Real-World Observational Study With 6 Months Follow-Up.
    Ostinelli EG; Cavallotti S; Castelnovo A; Guanella E; Gambini O; D'Agostino A
    J Clin Psychopharmacol; 2015 Oct; 35(5):553-8. PubMed ID: 26252438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of schizophrenia: clinical experience with asenapine.
    Cortese L; Bressan RA; Castle DJ; Mosolov SN
    J Psychopharmacol; 2013 Apr; 27(4 Suppl):14-22. PubMed ID: 23535351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.